ANAVEX LIFE SCIENCES CORP. 8K

Anavex Life Sciences reported Q3 2026 results showing a stock-compensation-driven profit, detailed regulatory and clinical progress for blarcamesine in Alzheimer’s, Rett syndrome, and Fragile X syndrome, and outlined steps to regain full Nasdaq compliance by filing delayed Form 10-Qs.

Anavex Life Sciences Corp. reported its third fiscal quarter 2026 financial results and provided a business update, highlighting regulatory progress for its lead drug candidate blarcamesine (ANAVEX2-73) across early Alzheimer’s disease, Rett syndrome, and Fragile X syndrome, while also addressing Nasdaq compliance. The company has submitted all Alzheimer’s clinical trial data to a newly opened U.S. IND and is using recent EMA scientific advice and prior FDA feedback to shape the design of a U.S. Phase 3 Alzheimer’s study (ANAVEX2-73-AD-005), supported by ongoing ADME and drug-drug interaction clinical pharmacology studies expected to complete key visits by the end of September. In Rett syndrome, blarcamesine has Orphan Drug, Rare Pediatric Disease, and Fast Track designations, and Anavex is initiating an adult Phase 3 trial (ANAVEX2-73-RS-005) while seeking FDA alignment to add pediatric patients and coordinating with the International Rett Syndrome Foundation. For Fragile X syndrome, the company plans to submit an IND to the FDA in September, building on existing Orphan Drug Designation. Financially, Anavex reported Q3 2026 net income of $7.8 million versus a prior-year loss, driven largely by reversals of stock-based compensation linked to termination of employees, primarily the former CEO, with cash and equivalents of $118.3 million expected to fund operations into mid to late fiscal 2028. The company also disclosed plans to file its outstanding Form 10-Qs for the second and third fiscal quarters of 2026 in the near term as part of its efforts to regain full compliance with Nasdaq listing requirements.

Filing Facts

CIK

1314052

Ticker

-

Form

8K

Source Type

sec

Accession

0001731122-26-001143

Alert Tier

7